Search filters
Update Reimbursement Scheme Jardiance® 10mg - Chronic Kidney Disease

Update Reimbursement Scheme Jardiance® 10mg - Chronic Kidney Disease

01/02/2024

From February 1, 2024, the use of Jardiance® (empagliflozin) in adult patients with chronic kidney disease, with and without...

Reimbursement Scheme Kesimpta®

Reimbursement Scheme Kesimpta®

03/11/2023

The health insurer does not fully reimburse Kesimpta® injvlst 50mg/ml pen 0,4ml. The producer of this medicine has therefore asked...

Update Reimbursement Scheme Forxiga® 10mg and Xigduo® 5mg

Update Reimbursement Scheme Forxiga® 10mg and Xigduo® 5mg

13/10/2023

TBR Nederland hereby informs you that from now on the conditions regarding the Reimbursement Scheme Forxiga® 10mg and Xigduo® 5mg...

Reimbursement Scheme Adhesa®

Reimbursement Scheme Adhesa®

08/09/2023

The health insurer does not fully reimburse Adhesa® 5 mg. The producer of this medicine has therefore asked TBR Nederland to...

Update Reimbursement Scheme Adempas®

Update Reimbursement Scheme Adempas®

06/09/2023

As off May 31st 2023, the reimbursement for Adempas® 0.5 mg and 1.0 mg is now also indicated for the treatment of PAH in pediatric...

You are currently offline. Some pages or content may fail to load.